P
6.72
0.13 (1.97%)
| Penutupan Terdahulu | 6.59 |
| Buka | 6.66 |
| Jumlah Dagangan | 1,986,893 |
| Purata Dagangan (3B) | 1,415,286 |
| Modal Pasaran | 703,125,888 |
| Harga / Jualan (P/S) | 9.32 |
| Harga / Buku (P/B) | 2.91 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Keuntungan | -98.10% |
| Margin Operasi (TTM) | -85.88% |
| EPS Cair (TTM) | -1.29 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 21.81% |
| Nisbah Semasa (MRQ) | 6.91 |
| Aliran Tunai Operasi (OCF TTM) | -42.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -23.09 M |
| Pulangan Atas Aset (ROA TTM) | -17.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Personalis, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.3
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.25 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 31.49% |
| % Dimiliki oleh Institusi | 46.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Merck & Co., Inc. | 31 Dec 2025 | 14,044,943 |
| Blue Water Life Science Advisors, Lp | 31 Dec 2025 | 1,676,300 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 13.00 (BTIG, 93.45%) | Beli |
| 13.00 (Guggenheim, 93.45%) | Beli | |
| Median | 12.50 (86.01%) | |
| Rendah | 10.00 (Morgan Stanley, 48.81%) | Pegang |
| Purata | 12.00 (78.57%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 9.22 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 05 Mar 2026 | 10.00 (48.81%) | Pegang | 8.56 |
| Needham | 27 Feb 2026 | 12.00 (78.57%) | Beli | 9.06 |
| BTIG | 11 Feb 2026 | 13.00 (93.45%) | Beli | 8.90 |
| 09 Jan 2026 | 12.00 (78.57%) | Beli | 8.10 | |
| Guggenheim | 26 Jan 2026 | 13.00 (93.45%) | Beli | 10.36 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors |
| 28 Jan 2026 | Pengumuman | Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference |
| 12 Jan 2026 | Pengumuman | Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ |
| 08 Jan 2026 | Pengumuman | Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |